Journal of Nanomedicine & Nanotechnology

A novel anis amide anchored nanocarrier for site specific/targeted delivery of bioactive: A preclinical study

3^rd International Conference on Nanotek & Expo

December 02-04, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

Neeraj K. Garg, Priya Dwivedi, B. Singh and O.P. Katare

Accepted Abstracts: J Nanomed Nanotechnol

Abstract:

Gemcitabine (2', 2'-difluorodeoxycytidine) is a deoxycytidine (nucleoside) analog with significant antitumor activity against variety of cancers including non-small cell lung cancer. However, rapid metabolism and shorter half-life of drug mandate higher dose and frequent dosing schedule which subsequently results into higher toxicity. Therefore, there is a need to design a vector which can reduce the burden of frequent dosing and higher toxicity associated with the use of gemcitabine. In this study, we investigated the possibility of improving the targeting potential by employing the surface modification on CTS/PEG NPs. We demonstrate formulation and characterization of chitosan/poly (ethylene glycol)-anisamide (CTS/PEG-AA) and compared its efficiency with CTS/PEG and free gemcitabine. Our results reveal its sizeable compatibility, comparatively less organ toxicity and higher antitumor activity in vitro as well as in vivo . This wealth of information surfaces the potential of CTS/PEG-AA nanoparticles as a potent carrier for drug delivery. In brief, this novel carrier opens new avenues for drug delivery which better meets the needs of anticancer research.